Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology at NASIT 2026
PRNewswire (Mon, 9-Mar 8:30 AM ET)
Baird Medical’s Global AI Surgical Push: New Software Expansion Targets U.S., EU, and China
Market Chameleon (Wed, 4-Mar 6:59 AM ET)
Baird Medical Accelerates Global Registration of AI-Driven Surgical Software
PRNewswire (Wed, 4-Mar 8:30 AM ET)
Market Chameleon (Mon, 2-Mar 5:32 AM ET)
Baird Medical Accelerates U.S. Expansion at NASOIE 2026
PRNewswire (Mon, 2-Mar 8:30 AM ET)
Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology
PRNewswire (Wed, 25-Feb 8:30 AM ET)
Market Chameleon (Fri, 20-Feb 6:07 AM ET)
Baird Medical to Showcase Minimally Invasive Thyroid Solutions at Upcoming US Clinical Conferences
PRNewswire (Thu, 19-Feb 8:30 AM ET)
Baird Medical Drives U.S. Market Penetration with Commercial Launch at Bakersfield Memorial Hospital
PRNewswire (Wed, 11-Feb 8:30 AM ET)
PRNewswire (Mon, 9-Feb 8:30 AM ET)
Baird Medical Investment Holdings Ltd is one of the microwave ablation medical device developers and providers in the PRC for minimally invasive treatment of tumors. Its proprietary medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Microwave ablation is a minimally invasive treatment technique that denaturalizes and coagulates the protein of tumor cells with extreme heat generated by microwave energy. Microwave ablation treatments have been applied to benign and malignant tumors, and the company believes the products are safer, minimally invasive and easier to operate with faster recovery periods and lower complication rates for patients, as compared to traditional treatment methods.
Baird Medical Investment Holdings - Ordinary Share trades on the NASDAQ stock market under the symbol BDMD.
As of March 11, 2026, BDMD stock price was flat at $2.75 with 293,853 million shares trading.
BDMD has a beta of -1.09, meaning it tends to be less sensitive to market movements. BDMD has a correlation of 0.02 to the broad based SPY ETF.
BDMD has a market cap of $101.00 million. This is considered a Micro Cap stock.
BDMD has underperformed the market in the last year with a return of -22.1%, while SPY returned +22.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BDMD shares. However, BDMD has outperformed the market in the last 3 month and 2 week periods, returning +93.7% and +50.3%, while SPY returned -0.8% and -1.1%, respectively. This indicates BDMD has been having a stronger performance recently.
BDMD support price is $2.34 and resistance is $3.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDMD shares will trade within this expected range on the day.